The $3 Billion Question: Kids, Scientists and CIRM
By David Jensen,
The California Stem Cell Report
| 08. 22. 2010
[Opinion]
Two California newspapers today offered quite different views of the world - one bleak and the other filled with hope. They implicitly captured the framework that will determine the fate of the state's $3 billion stem cell research effort.
In the simplest terms, it could boil down to school kids vs. stem cell researchers. Or it could be framed as school kids vs. the health of millions or in some other way that is more favorable to the California stem cell agency. And there could lie the fate of a measure - perhaps as early as 2012 - asking the people of California to pony up another $4 billion or so to pay for hundreds of more stem cell experiments.
But first, CIRM will have to overcome emotions generated by stories like those in The Sacramento Bee today. Reporters Diana Lambert and Melody Gutierrez wrote,
"Last year, public school districts started the year with fewer teachers, bigger classes and reduced resources.
"This year, it's worse."
Classes with 30 or more students are common, libraries are closing, buses are being eliminated...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
